Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading LKFT daily closes…
Loading price history…
Pipeline assets
GLPG3667
Stage not disclosed · Active
Target TYK2
Indications
Systemic lupus erythematosus (SLE)(Stage not disclosed)
Dermatomyositis (DM)(Stage not disclosed)
Status note Only product candidate disclosed in the filing; no phase, target or modality stated in excerpts. Company is winding down its cell therapy activities (no named cell therapy candidates disclosed) and is pursuing a business development strategy to acquire additional product candidates, in partnership discussions including Gilead.
Per-asset detail extracted from the 20-F filed 2026-03-26. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.